Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

micro-immunotherapeutic agent 2LXFS

An orally bioavailable micro-immunotherapeutic agent composed of various immune substances in diluted doses, with potential immunomodulating, anti-infective and anti-viral activities. The micro-immunotherapeutic agent 2LXFS contains various recombinant immunological active ingredients in low concentrations, including, but not limited to, cytokines, such as interleukin-1 (IL-1), IL-2, interferon alpha (IFN-a), IFN gamma (IFN-g), tumor necrosis factor alpha (TNF-a), and specific nucleic acids (SNAs) that are small synthesized oligonucleotides that prevent gene expression, such as the genes involved in viral replication. Upon oral administration of micro-immunotherapeutic agent 2LXFS, the active ingredients may help balance, restore and/or modulate the immune system. This may restore an adequate, re-adjusted anti-antiviral immune response. The formulation within each capsule is different and the levels of concentration of each substance can vary to allow stimulation, modulation and/or inhibition of the immune response in order to mimic what would naturally occur within the body. Therefore, the capsules are administered in a specific order.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:2LXFS
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search